-
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase III trial
Leia o artigo comentado por Dra. Cassia Regina Guedes Leal e Dra. Carmem Ferguson Theodoro: